Publication at First Faculty of Medicine |
2013
Abstract
AMPLIFY-EXT was randomized, double-blind study comparing two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months.
AMPLIFY-EXT proved extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) to reduce the risk of recurrent venous thromboembolism without increasing the rate of major bleeding.